DNAnexus Expands Relationship with Veeva to Advance Global Regulatory Collaboration DNAnexus, a global leader in regulatory cloud services, has announced the expansion of its collaboration with Veeva Systems, a prominent…
TriLink BioTechnologies® and Avantor® Partner to Expand Nucleic Acid Solutions in Europe TriLink BioTechnologies a Maravai® LifeSciences company and a global leader in providing cutting-edge life science reagents and services,…
D&D Pharmatech a clinical-stage biotechnology company dedicated to the development of disease-modifying therapeutics, has announced the successful completion of patient enrollment for DD01-DN-2, an ongoing Phase 2 clinical trial. This…
AdvanCell Closes Oversubscribed $112M Series C Funding AdvanCell, a pioneering clinical-stage radiopharmaceutical company focused on developing groundbreaking cancer therapeutics, has announced the successful closure of an oversubscribed US$112 million Series…
Cosette Pharmaceuticals a leading specialty pharmaceuticals company, has announced the appointment of Brad Leonard as Vice President, Generics Commercial Operations. This strategic move comes as the company continues its expansion…
Bayer has officially submitted a marketing authorization application to the European Medicines Agency (EMA), seeking approval for the use of finerenone in adult patients with heart failure (HF) with a…
Sionna Therapeutics Announces $150M IPO to Advance Cystic Fibrosis Drug Development Sionna Therapeutics, a Massachusetts-based biotechnology company specializing in cystic fibrosis (CF) treatments, has officially announced the terms of its…
Phase 3 Trial Pfizer has announced significant and positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER clinical trial. This trial assessed the efficacy of…
Inhalon Biopharma a clinical-stage biotechnology company focused on developing innovative treatments for acute respiratory infections (ARI), has announced a major milestone in the advancement of its inhaled antibody platform. The…
Median Technologies has announced a significant milestone in its mission to revolutionize lung cancer screening. The company’s proprietary artificial intelligence (AI) and machine learning (ML)-based software, eyonis™ Lung Cancer Screening…
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today that it has secured a reimbursement agreement with NHS England, providing eligible sickle cell disease (SCD) patients access to its groundbreaking CRISPR/Cas9 gene-edited therapy,…
Galderma’s Breakthrough Findings Galderma (SWX:GALD), a global leader in dermatology, has announced the results of its Phase IIIb RELAX clinical trial, demonstrating the rapid onset, long-lasting efficacy, and high patient…